1. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience
- Author
-
Steven M. Devine, Christina Matthews, Marcin Puto, Junan Li, Yvonne A. Efebera, Filiz Yucebay, Julianna Roddy, Basem M. William, Samantha Jaglowski, Don M. Benson, Sam Penza, Sumithira Vasu, and Leslie A. Andritsos
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Drug Resistance ,Graft vs Host Disease ,Kaplan-Meier Estimate ,Antibodies, Monoclonal, Humanized ,Single Center ,Gastroenterology ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,First line therapy ,Tocilizumab ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Acute graft versus host disease ,Humans ,Transplantation, Homologous ,Medicine ,Glucocorticoids ,Aged ,Retrospective Studies ,integumentary system ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Allografts ,Treatment Outcome ,surgical procedures, operative ,Oncology ,chemistry ,Hematologic Neoplasms ,030220 oncology & carcinogenesis ,Acute Disease ,Disease Progression ,Female ,Stem cell ,Steroid refractory ,business ,Complication ,Immunosuppressive Agents ,030215 immunology - Abstract
Acute graft-versus-host-disease (aGVHD) is a complication after allogeneic stem cell transplant. After the failure of treatment with high dose corticosteroids, steroid-refractory aGVHD (SR aGVHD) is associated with high rates of mortality. Tocilizumab has evidence of activity in SR aGVHD. For patients ineligible for trials, the OSU James Comprehensive Cancer Center has been utilizing tocilizumab as first-line therapy for SR aGVHD. We retrospectively report on 15 patients who received tocilizumab. aGVHD grading and responses were based on consensus criteria. Median age at transplant was 49 years. Median time to tocilizumab administration was 9 days (range, 3-16). Six patients had complete responses (40%) with a resolution of aGVHD. From the last contact, median overall survival for responders was not yet reached vs. 31 days for non-responders (
- Published
- 2019